SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis rescheduling could be on the horizon following reports of potential executive action. The community is actively discussing the implications of this policy change, particularly how it might trigger a short squeeze and impact the broader cannabis sector. Some are also pointing to Tilray's 'Liquid Diamond' vapes as a potential catalyst.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its cultural significance within the cannabis space and its positioning as a "culture coin" on the Solana network. Discussions also highlight potential synergies with broader cannabis reform and related stocks like $TLRY, with community members emphasizing the project's long-term vision.

Aventus Network

Aventus Network ($AVT) is trending as traders discuss a potential breakout, Polkadot integration, and recent strategic advisory appointment in the UAE. Bullish traders are highlighting its oversold conditions and low market cap as catalysts for a potential rally. Community members are closely monitoring volume and potential new exchange listings.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending after its earnings report triggered a volatile swing, initially rising on strong AI chip sales and guidance, but then sharply declining during the earnings call. Community discussion revolves around potential profit-taking, concerns about non-AI revenue, and the impact of comments made during the call. Despite strong fundamentals, the stock's reaction highlights the market's sensitivity to AI-related news and broader sector trends.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending amid growing community enthusiasm and strong bullish sentiment, with some drawing comparisons to previous meme coin successes. The community is rallying behind $YEE's potential as an ERC-20 token on Ethereum, emphasizing its momentum and strong fundamentals. Some community members believe $YEE could become a leading narrative in the crypto space.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors weigh its potential amid healthcare sector rotation and anticipation of a dividend payout. Technical analysts point to a possible breakout above the $340 resistance, while some community members speculate on news regarding ACA subsidies and potential DOJ developments as catalysts for a significant move. Despite some bearish sentiment, many see UNH as a long-term hold due to its leadership in the healthcare industry.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors digest better-than-expected earnings and revenue, alongside news of the CEO's upcoming departure which some see as a potential catalyst for innovation. Community discussions revolve around the company's guidance, share buybacks, and the potential for analyst upgrades. Bullish sentiment seems to be building on the prospect of new leadership and continued growth, particularly in the international market.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war with Paramount for Warner Bros. Discovery, with some investors hoping Netflix will abandon the deal and collect a $2.8 billion breakup fee, potentially boosting the stock; community chatter revolves around the deal's implications, regulatory hurdles, and potential impact on Netflix's financials and content strategy.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending amid discussions around its recent earnings, where the company beat EPS estimates but missed on revenue, leading to mixed reactions from investors. Community members are debating whether the stock's high PE ratio is justified, while others are focused on membership growth and digital sales. Some are speculating about a potential special dividend or stock split to attract more investors.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders eye whale short-covering behavior and potential institutional adoption. Community members are discussing potential partnerships and staking opportunities, as well as meme coins built on the Solana network. Some traders are calling for a breakout, while others express concerns about recent market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at month 3 and month 6 in the trial.</li><li>The company said that the results are supportive of a late-stage registrational trial.&nbsp;</li><li>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares.</li></ul>Shares of Rhythm Pharmaceuticals, Inc. (RYTM) jumped 14% on Thursday after the company announced that its mid-stage study evaluating Setmelanotide in Prader-Willi Syndrome patients showed reduction in weight and hyperphagia.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-preliminary-data-exploratory">said</a> that the reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at the third and sixth-month mark in the trial. The company said that the results are supportive of a late-stage registrational trial.<h2 class="st-heading-2">Trial Design</h2>The company enrolled 18 patients with Prader-Willi Syndrome (PWS) in the ongoing 52 week trial. Of this, 17 patients remain enrolled on active Setmelanotide therapy and the company will share additional data in the first half of 2026, it added.PWS is a rare genetic disorder requiring lifelong management and causing poor muscle tone and feeding issues in infancy, followed by relentless hunger (hyperphagia) and severe obesity in childhood, alongside developmental delays, learning disabilities, and distinctive behavioral problems. PWS is estimated to affect approximately 400,000 people worldwide and approximately 20,000 people in the United States, as per Rhythm.The company said that safety and tolerability profile of Setmelanotide therapy in the trial was consistent with the drug’s established clinical profile. In the United States, Setmelanotide is already indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to certain conditions including Bardet-Biedl syndrome.Rhythm is also looking to evaluate its experimental therapy RM-718 in PWS and expects the first patient with PWS to enter screening for this study in December.<h2 class="st-heading-2">Expert Take</h2>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares. The firm, which is "encouraged" by the preliminary update, argues that a successful late-stage study in PWS would "offer an attractive commercial opportunity."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/59;" src="data:image/png;base64,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" width="586" height="59" alt="RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits"><figcaption>RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RYTM">RYTM stock</a> has more than doubled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apollo-global-management-weighs-ipo-or-sale-of-invited-in-potential-deal-that-could-top-3-billion/cLIxS8NREnC">Apollo Global Management Weighs IPO Or Sale Of Invited In Potential Deal That Could Top $3B: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder 

 The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Equity

 The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.


<ul class="summary-bullets"><li>Brelovitug is a late-stage experimental drug being studied for chronic hepatitis delta virus infection.&nbsp;</li><li>The transaction with Bluejay is expected to close in the first quarter of 2026.</li><li>Mirum said it had secured $200 million through a private placement to be used to fund clinical development and commercial activities following the proposed acquisition.</li></ul>Shares of Mirum Pharmaceuticals, Inc. (MIRM) fell as much as 5% on Monday morning after the company announced that it has agreed to buy privately held Bluejay Therapeutics in a deal worth up to $820 million.The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio. Brelovitug is a late-stage experimental drug being studied for chronic hepatitis delta virus (HDV) infection, a most severe form of viral hepatitis in which nearly half of those affected progress to liver-related death within 10 years of diagnosis.<h2 class="st-heading-2">Deal Terms</h2>Under the deal, Mirum has <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251208788160/en/Mirum-Pharmaceuticals-Enters-into-Definitive-Agreement-to-Acquire-Bluejay-Therapeutics-Expanding-Global-Leadership-in-Rare-Disease">agreed</a> to acquire all outstanding shares of Bluejay for $250 million in cash and $370 million in Mirum common stock, in addition to potential sales-based milestone payments of up to $200 million in cash.The transaction with Bluejay is expected to close in the first quarter of 2026, subject to regulatory approval and other customary closing conditions, the company added.<h2 class="st-heading-2">About the Liver Drug&nbsp;</h2>Brelovitug is currently in late stage trials for HDV. In mid-stage trials, Brelovitug demonstrated strong antiviral activity in HDV and improvements in liver enzyme levels and a favorable safety profile.Mirum said on Monday that it expects top-line data from the late-stage trial in the second half of 2026, with application to the FDA for potential approval slated for 2027.Mirum also said that it will evaluate strategic options for Bluejay’s additional investigational programs after closing of the deal.<h2 class="st-heading-2">Placement Announcement</h2>Mirum on Monday also said that it has entered into a definitive agreement with a syndicate of existing and new healthcare investors, for the sale of Mirum common stock and pre-funded warrants, in a private placement.The private placement is expected to result in gross proceeds of $200 million which will be used to fund clinical development and commercial activities following the proposed acquisition, the company said.<h2 class="st-heading-2">Expert Take</h2>Cantor Fitzgerald subsequently raised the price target on Mirum to $130 from $95, while keeping an ‘Overweight’ rating on the shares. The new price target represents a potential upside of about 90% from the stock’s closing price on Friday.Cantor opined that Mirum’s proposed acquisition of Bluejay under the agreed-upon terms is a “steal.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MIRM">MIRM</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:586/57;" src="data:image/png;base64,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" alt="MIRM’s Sentiment Meter and Message Volume as of 11:13 a.m. ET on Dec. 08, 2025 | Source: Stocktwits" width="586" height="57"><figcaption>MIRM’s Sentiment Meter and Message Volume as of 11:13 a.m. ET on Dec. 08, 2025 | Source: Stocktwits</figcaption></figure>MIRM stock has gained 64% this year and by about 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-chip-chief-reportedly-dismisses-concerns-about-exit/cLIYHDjREmk">Apple Chip Chief Reportedly Dismisses Concerns About Exit: ‘I Love My Job’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal'

The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio.

<ul class="summary-bullets"><li>The company said that the fraud impacted the company’s financial statement in multiple ways and anticipates filing new financial statements shortly.</li><li>An executive said that the cost of the Lugano fraud will, by a wide margin, represent the most significant loss Cody has experienced since its inception.</li><li>Retail investors, analysts await restated financial statements.</li></ul>Shares of Compass Diversified (CODI) fell a steep 18% on Friday after the company announced it must restate its financial results for fiscal year 2022 to 2024 after its probe led to findings of fraud at its subsidiary Lugano.The company has removed financial information for the years 2022 to 2024 from its website, citing non-reliance.“I want to begin by saying that this has been, without question, the most challenging period in Cody's history,” CEO Elias Sabo said in a call. He further added that the fraud at Lugano was “pervasive, complex and isolated to that business.”<h2 class="st-heading-2">Probe And Findings</h2>Compass Diversified announced in early May that its audit committee has initiated an investigation into the financing, accounting, and inventory practices of Lugano. The subsidiary’s CEO Moti Ferder subsequently resigned from the company without any severance compensation.As per Sabo, Ferder and his family have fled the U.S. and permanently relocated to Israel. The audit committee probe has concluded and discovered “deliberate and systemic fraud,” he added.“The former Lugano CEO engaged in a scheme to significantly overstate Lugano's sales and profits, misrepresent the existence and value of Lugano's inventory, and keep potential financial liabilities off Lugano's books and records. His efforts to hide his fraud were extensive,” Sabo said. He added that Ferder created fake sales transactions to inflate Lugano’s reported revenues, claimed inventory that either didn't exist or didn’t belong to Lugano and entered numerous financing agreements with third parties that he kept off the company’s balance sheet.<h2 class="st-heading-2">Impact Of The Fraud</h2>CODI is a holding company that acquires and actively manages middle-market businesses. It acquired Lugano Diamonds &amp; Jewelry, Inc., a designer, manufacturer and marketer of one-of-a-kind jewelry in September 2021.The company said that the fraud impacted the company’s financial statement in multiple ways and anticipates filing new financial statements shortly. The company also intends to file its first, second, and third quarter 2025 financials over the coming weeks.“At a high level, the restatement significantly reduced our reported inventory. Consolidated inventory for 2024 was reduced by greater than $375 million, or nearly 40%...further, Lugano's revenue declined by more than 85% from previously reported levels following the removal of the fraudulent revenue,” a company executive said.Lugano filed for Chapter 11 protection under the U.S. Bankruptcy Code on November 16. “Regardless of what we ultimately recover from Lugano bankruptcy, the cost of the Lugano fraud will, by a wide margin, represent the most significant loss Cody has experienced since its inception,” the executive added.<h2 class="st-heading-2">Analyst Take</h2>According to William Blair, who has an ‘Outperform’ rating on the shares, Compass Diversified is worth at least $10 per share excluding Lugano. The firm said that it now awaits the restated financials.Blair's "back-of-the-envelope" estimate suggests Compass would need to raise about $500 million to reach its target leverage. Excluding Lugano, the company's 2025 subsidiary core profit results are tracking in line with expectations of mid-single-digit growth to $330 million-$360 million, the firm added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around Lugano jumped from ‘Neutral’ to ‘Bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user said that they will stick with the company for now and highlighted that the company’s other subsidiaries seem to be doing well and expressed anticipation for restated financials. &nbsp;<stembedurl>https://stocktwits.com/MplsBarry/message/638306243</stembedurl>Another slammed the company management for failing to identify the fraud at Lugano earlier.<stembedurl>https://stocktwits.com/SnapCrackleStop/message/638278242</stembedurl><a href="https://stocktwits.com/symbol/CODI">CODI stock</a> has dropped 74% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/new-york-times-sues-perplexity-ai-over-unauthorized-content-use-what-does-the-lawsuit-say/cLISBqyREko">New York Times Sues Perplexity AI Over Unauthorized Content Use: What Does The Lawsuit Say?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Compass Diversified Stock Plunges On ‘Most Significant Loss’ After Fraud Forces Removal Of Three Years Of Financials

The company has removed financial information for the years 2022 to 2024 from its website, citing non-reliance. 

 A window display of actress Sydney Sweeney is seen on a window of an American Eagle store on August 01, 2025 in New York City. 

American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act

AEO appears to have gotten its brand marketing right, and the additional expense on its balance sheet to fuel celebrity partnerships is paying off.

<ul class="summary-bullets"><li>Archer is looking to pursue both defense and commercial opportunities with its aircrafts.</li><li>The company first announced its intention to build a military aircraft through a partnership with Anduril in December 2024.</li><li>A Stocktwits user said that they are bullish on the stock but want to see material results and flight tests.</li></ul>Shares of Archer Aviation Inc. (ACHR) jumped 3% on Tuesday after the company announced an exclusive collaboration with California-headquartered Karem Aircraft aimed at gaining access to the latter’s military grade technology.Archer <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251202660206/en/Archer-and-Karem-Aircraft-Announce-Exclusive-Collaboration-to-Utilize-Military-Grade-Rotor-Technology-on-Archers-Next-Generation-Dual-Use-VTOL-Aircraft">said</a> that the collaboration is aimed at accessing privately-held Karem’s military-grade rotor and tiltrotor technologies for integration into Archer’s next-generation autonomous, hybrid-propulsion VTOL aircraft. The company is looking to pursue both defense and commercial opportunities with its aircrafts.<h2 class="st-heading-2">Archer’s Military Aircraft Goals</h2>Archer Aviation first announced its intention to build a military aircraft through a partnership with Anduril in December 2024. Earlier this year, the company also announced two strategic acquisitions to accelerate its development.Archer acquired a patent portfolio and hired critical employees from Overair, a spin-off of Karem Aircraft. It also acquired key composite manufacturing assets and an approximately 60,000 square foot manufacturing facility from Mission Critical Composites, a specialized defense composite manufacturer in Southern California in August.The company expects the combined assets to enable an aircraft with the speed, range, payload, and low-thermal and acoustic signatures necessary for missions across contested airspace.“Karem’s military-grade rotor systems are among the most advanced Army-validated technologies in the world. Integrating them into our next-gen hybrid VTOL platform positions Archer to move faster and deliver capabilities that legacy systems simply can’t match,” said Archer CEO Adam Goldstein.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHR">ACHR</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.One user said, “less talk and more action needed from management. Where are the flight tests? Where are the new aircraft? Bullish, but it's time to show results.”<stembedurl>https://stocktwits.com/burnaboi278/message/637903665</stembedurl>Last month, Hunterbrook Capital <a href="https://stocktwits.com/news-articles/markets/equity/hunterbrook-capital-reveals-short-position-in-evtol-maker-archer-aviation/cLPMHyAREfG">revealed</a> a short position in Archer after noting that its flagship Midnight electric air taxi never flew at the 2025 Dubai Airshow.ACHR stock is down by 21% this year and up by about 5% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-us-sales-slip-in-november-on-weakening-demand-for-evs/cLIaoQuREKf">Ford US Sales Slip In November On Weakening Demand For EVs After Federal Tax Credit Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Archer Aviation logo is displayed on a smartphone screen. (Photo by Cheng Xin/Getty Images)

Archer Aviation Stock Jumps On Tech Deal With Karem For Military Aircraft — Retail Seeks Tangible Progress

Archer said that the collaboration is aimed at accessing privately-held Karem’s military-grade rotor and tiltrotor technologies for integration into Archer’s next-generation autonomous, hybrid-propulsion VTOL aircraft.

<ul class="summary-bullets"><li>In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness.</li><li>The company intends to meet the FDA’s additional clinical data requirement with the HOPE-3 study and expects a review period of up to six months for the resubmitted application.</li><li>‘Pharma Bro’ Martin Shkreli announced a short position in Capricor last week.&nbsp; &nbsp;</li></ul>Capricor Therapeutics stock drew heavy retail attention on Monday as retail investors are now awaiting data from the biotechnology company’s HOPE-3 study in the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks and within the fourth quarter. The company intends to submit an application to the U.S. Food and Drug Administration based on the study data. According to the firm, 105 DMD patients have been enrolled in the recent trial.<h2 class="st-heading-2">Capricor’s Rigged Road With Deramiocel Approval</h2>In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data. The company intends to meet the FDA’s additional clinical data requirement with the HOPE-3 study and expects a review period of up to six months for the resubmitted application.Commercial launch preparations are underway to support market introduction in 2026, the company said in November.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,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" width="583" height="60" alt="CAPR’s Sentiment Meter and Message Volume as of 3:15 p.m. ET on Dec. 1, 2025 | Source: Stocktwits"><figcaption>CAPR’s Sentiment Meter and Message Volume as of 3:15 p.m. ET on Dec. 1, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user noted that the company’s data is the best to date despite the small sample size. However, they added that, “betting against the data without seeing it is very dangerous. As a poet once said "A little knowledge is a dangerous thing, drink deep or taset not the perian spring."<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/637821091</stembedurl>Another bearish user said, “smell bad, look a like ols [old] bad news from several biotech.”<stembedurl>https://stocktwits.com/rudazur2/message/637822514</stembedurl><h2 class="st-heading-2">Short Positions And Pessimism On Trial Data</h2>Last week, former biotech executive and businessman Martin Shkreli <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">announced</a> his short position in Capricor and opined that Deramiocel will not yield positive results in the HOPE-3 study.Shkreli highlighted concerns, including limitations in cell therapies' ability to reach target tissue and other safety issues, provided they are derived from donor hearts and are not immunoprivileged cells.He further alleged that data from the company’s previous HOPE-2 trial was not meaningful. “Note the company and the publication reported a successful PE met, but the FDA disagreed,” he said.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 51% this year and by about 66% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/q32-bio-stock-soars-on-selling-experimental-drug-to-akeba-for-to-592-million/cLI7lHgRE0c">Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout

Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks. 

The Kohl'scorporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Kohl’s Traders Just Got The CEO They Wanted — And the Stock’s Weekly Breakout Says It All

Last week, KSS stock soared nearly 60%, marking its best weekly performance this year, after Michael Bender was confirmed as full-time CEO.

<ul class="summary-bullets"><li>The postponement was to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company said.&nbsp;</li><li>Vanda continues to expect the agency to decide on its application seeking approval for Tradipitant for the prevention of vomiting induced by motion by December 30.&nbsp;</li><li>The company said it has commenced discussions on the drug’s proposed labeling.</li></ul>Vanda Pharmaceuticals Inc. (VNDA) said on Friday that the U.S. Food and Drug Administration (FDA)’s re-review of the clinical hold on long-term clinical studies of Tradipitant in motion sickness has been extended.The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5 to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-provides-regulatory-update-on-tradipitant-for-motion-sickness-302627878.html">said</a>.<h2 class="st-heading-2">Fresh Dates</h2>Vanda expects the agency to decide on its application seeking approval for Tradipitant for the prevention of vomiting induced by motion by December 30, according to previous schedule.The company said it has commenced discussions on the drug’s proposed labeling.Vanda licensed Tradipitant from American drugmaker Eli Lilly and Company. It is being developed for multiple conditions, including gastroparesis, motion sickness, and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.Earlier this month, the company announced that Tradipitan reduced nausea and vomiting induced by GLP-1 drug Wegovy in overweight and obese adults by about 50%. The company is looking forward to a late-stage trial for the condition in the first half of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of VNDA traded 3% higher on Friday morning. On Stocktwits, retail sentiment around VNDA stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user highlighted that the company does not expect a delay in its drug application decision.<stembedurl>https://stocktwits.com/Massimo21/message/637642514</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> is up by 14% this year and by 6% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/baidu-reportedly-begins-layoffs-in-bid-to-cut-costs-after-disappointing-quarter/cL5aTUpRELQ">Baidu Reportedly Begins Layoffs In Bid To Cut Costs After Disappointing Quarter, AI Roles Largely Safe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review 

The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5.

<ul class="summary-bullets"><li>Barclays noted that the company matched estimates on sales and beat on earnings, driven by continued strength at Hollister, with 15% comparable sales growth.</li><li>The firm said that it sees strong momentum for Abercrombie heading into the holiday season.</li><li>Morgan Stanley on Wednesday raised the firm's price target on Abercrombie &amp; Fitch to $95 from $78 and maintained an ‘Equal Weight’ rating.</li></ul>Abercrombie &amp; Fitch was one of the top-trending tickers on Stocktwits&nbsp;on Friday&nbsp;after Barclays raised the firm's price target, noting the company's third-quarter results this week showcased the continued strength of its Hollister brand.Barclays raised its price target on Abercrombie &amp; Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly. The firm noted that the company matched estimates on sales and beat on earnings, driven by continued strength from Hollister with 15% comp salesBarclay said that it sees strong momentum for Abercrombie heading into the holiday season.<h2 class="st-heading-2">Abercrombie’s Better-Than-Expected Q3 Results</h2>On Tuesday, the company’s third-quarter net sales rose 7% to $1.29 billion, compared with Wall Street estimates of $1.28 billion, according to data from Fiscal AI. Abercrombie’s quarterly adjusted earnings per share came in at $2.36, compared with expectations of $2.17.Abercrombie also raised the lower end of its annual net sales and profit forecasts heading into the holiday season, betting on growing demand for its namesake brand and Hollister’s products.<h2 class="st-heading-2">Analysts’ Take</h2>Morgan Stanley on Wednesday raised the firm's price target on Abercrombie &amp; Fitch to $95 from $78 and maintained an ‘Equal Weight’ rating. The third-quarter beat "surprised to the upside,” and the firm leaves the report more constructive as Abercrombie’s financial profile "may be structurally better than we thought," Morgan Stanley said.UBS analysts noted that Abercrombie's results and improved guidance highlight its strong fundamentals and noted that the firm sees potential for an earnings per share (EPS) compound annual growth rate of 14% following FY25.Retail sentiment on Abercrombie remained unchanged in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/ANF">Shares of Abercrombie</a> have declined by over 36% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/from-walmart-to-best-buy-retailers-see-a-solid-start-to-holiday-quarter/cL5aGzmRELI">From Walmart To Best Buy, Retailers See A Solid Start To Holiday Quarter – But Consumers Are Waiting For Discounts</a>

General view of the Abercrombie and Fitch store in Carnaby Street.

Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum

Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly.

<ul class="summary-bullets"><li>Redemplo was approved by the FDA earlier this month, marking a milestone for Arrowhead as it becomes a commercial-stage company.</li><li>The company said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis.</li><li>Arrowhead reported revenue of $829.4 million in fiscal year 2025, compared to $3.55 million in FY24.</li></ul> Morgan Stanley on Wednesday raised its price target on Arrowhead Pharmaceuticals (ARWR) to $48 from $45 while keeping an ‘Equal Weight’ rating on the shares.Shares of the company traded 22% higher at the time of writing on Wednesday morning.According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)." Severe hypertriglyceridemia refers to a medical condition where there are dangerously high levels of triglycerides in the blood.<h2 class="st-heading-2">Significance Of Redemplo Approval</h2>Redemplo is Arrowhead’s first FDA-approved medicine. Its approval earlier this month as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome marked a milestone for Arrowhead as it evolves into a commercial-stage pharmaceutical company.Familial chylomicronemia syndrome (FCS) is a rare, genetic disorder where the body cannot properly break down fat, leading to extremely high levels of triglycerides in the blood. Arrowhead estimates that about 6,500 people in the U.S. are living with FCS.“Arrowhead is truly just getting started, and we are well-positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years,” Arrowhead CEO Christopher Anzalone said on Tuesday.The company also said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis due to high triglyceride levels.<h2 class="st-heading-2">FY25 Earnings</h2>Arrowhead <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results/">reported</a> revenue of $829.4 million in fiscal 2025 (FY25), compared to $3.6 million in FY24, and above an analyst estimate of $757.44 million.Net loss per share came in at $0.01, down from the loss of $5 reported in FY24, and lower than an analyst estimate of a loss of $0.03 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ARWR jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume remained at 'high' levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than tripled this year and risen by about 172% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-posts-unexpected-loss-in-q3-as-ev-sales-drop/cL53uOfREWq">Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."

iShares Trust - iShares Russell 2000 BuyWrite ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$39.48
Prev Close	$39.47
Open	$39.51
Dividend Yield	N/A
50-Day Moving Average	$40.11
Beta	N/A
Avg. Volume	11,327.74
PE Ratio	N/A

52-Week High	$47.73
52-Week Low	$34.29
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWMW News

IWMWiShares Russell 2000 BuyWrite ETF